Navigation Links
New research shows benefits of ultrasound contrast agents outweigh potential risk to heart patients
Date:3/31/2008

ST. LOUIS A Saint Louis University cardiologist called upon the U.S. Food and Drug Administration (FDA) today to reconsider a strong warning it recently placed on a diagnostic tool, stating that the warning could prevent doctors from detecting life-threatening cardiac events.

In October 2007, the FDA placed a black box warning on ultrasound contrast agents, which are used to improve the quality of echocardiography images in patients who do not otherwise have optimal images, after receiving reports of four deaths and serious reactions shortly after or during the infusion.

A black box warning is given to drugs that carry a significant risk of serious or even life-threatening adverse effects. The warning placed on ultrasound contrast agents was issued without a formal examination of the risks and benefits of using them, says Melda Dolan, M.D., associate professor of cardiology at Saint Louis University School of Medicine.

Dolans research shows that the contrast agents are indeed safe, and withholding their use, which has occurred since the FDA warning, would make diagnosis of life-threatening heart disease more difficult.

Based on the results of our study, we believe the FDA should reconsider its stance on contrast agents because the benefits outweigh the potential, although not established, risk, says Dolan, who is the primary investigator of the study.

Dolan presented the research findings today at the 57th annual American College of Cardiology Scientific Session in Chicago, Ill.

Routinely used to determine the strength of the heart, echocardiography enables cardiologists to monitor a patients cardiac function, determine if treatment plans are working and can be used to pursue further modes of therapy. However, various factors can prevent the echocardiogram from obtaining optimal images.

In 1997, after significant scrutiny, the FDA approved the use of ultrasound contrast agents, which are gas-filled microbubbles that are administered intravenously into the blood, for these cases. The use of contrast agents to get optimal images is necessary in approximately one out of five individuals, says Arthur Labovitz, M.D., director of the division of cardiology at Saint Louis University and a contributing researcher to the project.

Ultrasound contrast agents are important because they greatly enhance not only the quality of the images taken with the echocardiogram, but also the doctors ability to assess the function of the heart, Dolan explained.

The purpose of this study was to evaluate the overall risk and benefits of ultrasound contrast agents. Using results from two university hospitals, the researchers examined the clinical outcomes of nearly 24,000 patients who received contrast agents during an echocardiogram and compared their results to those from a group of approximately 6,000 patients who did not need to receive contrast agents.

To test the safety of contrast agents, the researchers looked at the short-term (within 30 minutes of the infusion) and long-term (within 24 hours) outcomes and noted any serious adverse events or deaths. Of the nearly 24,000 individuals to receive the contrast agents, not one experienced an adverse event within 30 minutes. One death and three non-fatal heart attacks occurred within 24 hours; however these could not be attributed to the contrast agents.

Our research indicates that contrast agents can be safely used in these patients to provide optimal imaging, Labovitz said.

To test the efficacy of ultrasound contrast agents, the researchers compared echocardiogram images, which were enhanced by contrast agents, with images of patients who did not need contrast agents. They found the images of both equally clear.

Optimal echocardiography images make it possible for cardiologists to detect and treat potentially fatal coronary heart disease. This ability, Dolan says, is the most significant benefit of ultrasound contrast agents.

To test this benefit, the researchers looked at the long-term survival rate of patients who received contrast agents during pharmaceutical stress echocardiogram exams and those who did not. They found nearly identical rates of death between both groups.

The message that patients should take home from our study is that there are risks to every treatment, from medications to surgery. In the field of health care, there are no guarantees. But when the benefits of a treatment or test greatly outweigh the risks, it may be worthwhile to take a small risk for a great benefit, Dolan said.


'/>"/>

Contact: Sara Savat
ssavat@slu.edu
314-977-8018
Saint Louis University
Source:Eurekalert

Related medicine news :

1. Researchers study why high school boys dodge Phys Ed
2. Researchers Successfully Test Ebola Vaccines
3. Researchers identify a gene responsible for cases of Lou Gehrigs disease
4. Researchers identify a gene responsible for Lou Gehrigs disease
5. MediPurpose Supports Diabetes Research Effort
6. First national autism registry shows notable impact on autism research in opening year
7. Gamma Secretase Modulators Show Promise in Alzheimers Disease Animal Model Efficacy Studies, According to Research Conducted by TorreyPines Therapeutics
8. Preschool kids do better when they talk to themselves, research shows
9. Baxa Corporation Launches Call for Research Papers
10. American Association for Dental Research holds 37th annual meeting
11. SUNY researcher issued patent for virtual telemicroscope
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... ... recently completed Course II of the HP3 (High-Performance Periodontal Practice) continuing education (CE) ... learning the latest advancements in his field by attending numerous CE courses each ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... offering holistic pediatric dentistry options for its patients on Long Island, New York. ... entire physical well being, and is one of the biggest trends in dentistry ...
(Date:5/24/2017)... ... May 24, 2017 , ... Dymedix® ... diagnostics sensors, announced today it had completed the first phase of building a ... domestic and rest of world (ROW) authorized dealers specializing in polysomnography accessories. ...
(Date:5/23/2017)... MA (PRWEB) , ... May 23, 2017 , ... ... claim in North Carolina have remained steady since 2009, according to a Workers ... era. , The study Monitoring the North Carolina System: CompScope™ Benchmarks, 17th ...
(Date:5/23/2017)... , ... May 23, 2017 , ... ... and Reconstructive Surgeon Dr. Kevin Sadati, is pleased to announce a new treatment ... collagen and elastin in their face, neck, and body through a virtually pain-free, ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... , May 10, 2017  The Corporate Whistleblower ... employees of sleep therapy clinics to call us ... therapy clinic is involved in a substantial scheme ... in hearing from an employee of a medical ... a kickback scheme to provide medical practice groups with ...
(Date:5/9/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... has earned a spot on Forbes, "America,s ... ranked among 500 U.S. employers as well as in ... Services. The annual Forbes rankings ... of over 30,000 employees across 25 industries. The survey ...
(Date:5/9/2017)... Ore. , May 9, 2017  Semler ... that provides technology solutions to improve the clinical ... financial results for the first quarter ended March ... our products enable our customers to identify when ... to intervene before events like heart attacks or ...
Breaking Medicine Technology: